Notes to the Consolidated Financial Statements of the Bayer Group

Key Data by Segment and Region

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

2015

2016

 

2015

2016

 

2015

2016

 

2015

2016

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

For definition see Combined Management Report, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

15,308

16,420

 

6,076

6,037

 

10,128

9,915

 

1,490

1,523

Change1

 

+13.3%

+7.3%

 

+43.1%

−0.6%

 

+9.2%

−2.1%

 

+13.1%

+2.2%

Currency-adjusted change1

 

+8.7%

+8.7%

 

+40.4%

+3.5%

 

+2.4%

+0.2%

 

+4.5%

+4.8%

Intersegment sales

 

38

29

 

2

5

 

34

36

 

20

10

Net sales (total)

 

15,346

16,449

 

6,078

6,042

 

10,162

9,951

 

1,510

1,533

Other operating income

 

154

207

 

108

101

 

643

301

 

4

10

EBIT1

 

3,028

3,389

 

768

695

 

2,094

1,755

 

254

313

EBIT before special items1

 

3,327

3,947

 

1,005

987

 

1,872

1,898

 

318

320

EBITDA before special items1

 

4,616

5,251

 

1,456

1,411

 

2,406

2,421

 

347

349

ROCE1

 

14.4%

16.2%

 

4.0%

3.5%

 

16.3%

12.9%

 

47.8%

63.5%

Net cash provided by operating activities

 

3,157

3,368

 

816

874

 

749

2,071

 

348

193

Equity-method income (loss)

 

1

 

2

 

(1)

(1)

 

Equity-method investments

 

3

3

 

11

11

 

4

15

 

Assets

 

22,389

22,173

 

16,560

16,558

 

14,230

14,868

 

791

838

Capital expenditures

 

764

851

 

182

220

 

735

773

 

43

39

Additions to noncurrent assets from acquisitions

 

(145)

(3)

 

149

(1)

 

98

(10)

 

Depreciation, amortization and impairments

 

1,347

1,695

 

454

601

 

534

525

 

63

30

of which impairment losses

 

62

464

 

25

175

 

35

52

 

34

1

of which impairment loss reversals

 

(1)

 

 

 

(1)

Liabilities

 

8,385

8,941

 

1,596

1,614

 

5,344

5,897

 

678

699

Research and development expenses

 

2,450

2,787

 

250

259

 

1,082

1,164

 

134

140

Number of employees (as of Dec. 31)2

 

40,504

40,093

 

13,513

12,821

 

23,268

22,399

 

3,804

3,957

Key Data by Segment – continued

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

2015

2016

 

2015

2016

 

2015

2016

 

2015

2016

 

2015

2016

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

For definition see Combined Management Report, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

1,097

1,042

 

4

6

 

34,103

34,943

 

11,982

11,826

 

46,085

46,769

Change1

 

−1.3%

−5.0%

 

−42.9%

+50.0%

 

+15.7%

+2.5%

 

+2.8%

−1.3%

 

+12.1%

+1.5%

Currency-adjusted change1

 

−0.8%

−4.2%

 

−42.9%

 

+10.7%

+4.7%

 

−5.1%

0.0%

 

+6.2%

+3.5%

Intersegment sales

 

2,249

2,124

 

(2,407)

(2,279)

 

 

64

75

 

Net sales (total)

 

3,346

3,166

 

(2,403)

(2,273)

 

 

12,046

11,901

 

46,085

46,769

Other operating income

 

69

91

 

64

77

 

1,042

787

 

67

111

 

1,109

898

EBIT1

 

(39)

(50)

 

(499)

(364)

 

5,606

5,738

 

635

1,304

 

6,241

7,042

EBIT before special items1

 

43

18

 

(472)

(344)

 

6,093

6,826

 

967

1,304

 

7,060

8,130

EBITDA before special items1

 

238

224

 

(466)

(338)

 

8,597

9,318

 

1,659

1,984

 

10,256

11,302

ROCE1

 

 

 

10.4%

10.3%

 

7.1%

15.3%

 

9.9%

11.0%

Net cash provided by operating activities

 

27

503

 

287

(574)

 

5,384

6,435

 

1,452

1,824

 

6,836

8,259

Equity-method income (loss)

 

 

(7)

 

(6)

 

(9)

(20)

 

(9)

(26)

Equity-method investments

 

 

1

325

 

19

354

 

227

230

 

246

584

Assets

 

2,324

2,632

 

8,263

15,986

 

64,557

73,055

 

9,360

9,183

 

73,917

82,238

Capital expenditures

 

311

307

 

5

18

 

2,040

2,208

 

514

419

 

2,554

2,627

Additions to noncurrent assets from acquisitions

 

 

 

102

(14)

 

27

 

129

(14)

Depreciation, amortization and impairments

 

195

206

 

6

6

 

2,599

3,063

 

733

680

 

3,332

3,743

of which impairment losses

 

4

7

 

 

160

699

 

69

13

 

229

712

of which impairment loss reversals

 

 

 

(1)

(1)

 

 

(1)

(1)

Liabilities

 

4,814

5,616

 

23,915

23,724

 

44,732

46,491

 

3,740

3,850

 

48,472

50,341

Research and development expenses

 

32

39

 

64

16

 

4,012

4,405

 

262

261

 

4,274

4,666

Number of employees (as of Dec. 31)2

 

19,015

19,494

 

709

828

 

100,813

99,592

 

15,770

15,578

 

116,583

115,170

Key Data by Region

 

 

Europe / Middle East / Africa

 

North America

 

Asia / Pacific

 

 

2015

2016

 

2015

2016

 

2015

2016

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

For definition see Combined Management Report, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external) – by market

 

17,707

17,823

 

12,621

12,806

 

10,263

11,032

Change1

 

+5.0%

+0.7%

 

+28.0%

+1.5%

 

+13.2%

+7.5%

Currency-adjusted change1

 

+5.6%

+2.8%

 

+10.8%

+2.0%

 

+1.4%

+7.9%

Net sales (external) – by point of origin

 

18,528

18,808

 

12,332

12,375

 

10,022

10,786

Change1

 

+5.4%

+1.5%

 

+27.3%

+0.3%

 

+13.6%

+7.6%

Currency-adjusted change1

 

+6.1%

+3.5%

 

+9.5%

+0.8%

 

+1.5%

+8.1%

Interregional sales

 

10,340

10,745

 

3,994

4,280

 

828

912

Other operating income

 

580

331

 

109

223

 

107

126

EBIT1

 

4,119

4,673

 

1,483

1,128

 

547

1,165

Assets

 

34,145

39,146

 

20,522

21,088

 

9,492

9,831

Capital expenditures

 

1,442

1,549

 

587

628

 

402

299

Depreciation, amortization and impairments

 

1,874

1,997

 

834

1,181

 

496

479

Liabilities

 

29,116

30,506

 

13,461

13,478

 

3,583

3,428

Research and development expenses

 

2,944

3,285

 

1,051

1,081

 

214

229

Number of employees (as of Dec. 31)2

 

58,839

59,483

 

15,961

15,788

 

28,818

27,407

Key Data by Region – continued

 

 

Latin America

 

Reconciliation

 

Total

 

 

2015

2016

 

2015

2016

 

2015

2016

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

For definition see Combined Management Report, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external) – by market

 

5,494

5,108

 

 

46,085

46,769

Change1

 

+3.2%

−7.0%

 

 

+12.1%

+1.5%

Currency-adjusted change1

 

+7.7%

+0.8%

 

 

+6.2%

+3.5%

Net sales (external) – by point of origin

 

5,203

4,800

 

 

46,085

46,769

Change1

 

+3.4%

−7.7%

 

 

+12.1%

+1.5%

Currency-adjusted change1

 

+8.7%

+0.6%

 

 

+6.2%

+3.5%

Interregional sales

 

582

530

 

(15,744)

(16,467)

 

Other operating income

 

313

218

 

 

1,109

898

EBIT1

 

591

440

 

(499)

(364)

 

6,241

7,042

Assets

 

5,079

5,823

 

4,679

6,350

 

73,917

82,238

Capital expenditures

 

123

151

 

 

2,554

2,627

Depreciation, amortization and impairments

 

122

80

 

6

6

 

3,332

3,743

Liabilities

 

1,486

1,599

 

826

1,330

 

48,472

50,341

Research and development expenses

 

65

71

 

 

4,274

4,666

Number of employees (as of Dec. 31)2

 

12,965

12,492

 

 

116,583

115,170